

JENNY ZHOU, PH.D.
Vice President

Office: +44 20 3480 7931
Fax: +44 20 3480 7901
Jenny.Zhou@analysisgroup.com

1 Angel Court
London EC2R 7HJ
United Kingdom

Based in Analysis Group's London office, Dr. Zhou is a health economist with extensive experience in health economics and outcomes research. Her expertise includes economic evaluation, health technology assessment, and comparative effectiveness research using clinical and real-world evidence. Dr. Zhou has developed evidence submissions – including systematic literature reviews, indirect treatment comparisons, and cost-effectiveness analyses – for health technology appraisals in the UK, EU, and Canada. She also has extensive experience supporting clients through the ICER review process in the US. Dr. Zhou's additional research has involved evaluating Medicare's Oncology Care Model (OCM) program; assessing disease burden of illness and treatment patterns; and developing pharmaceutical pricing strategies based on early stage modeling. Her experience encompasses a wide range of therapeutic areas, including oncology and hematology, rare bleeding disorders, genetic diseases, autoimmune diseases, mental health disorders, cardiovascular diseases, and infectious diseases. Dr. Zhou's work has been published in many peer-reviewed journals and featured at numerous conferences.

EDUCATION

2011 Ph.D., pharmaceutical economics and policy, University of Southern California
2008 M.S., pharmaceutical economics and policy, University of Southern California
2006 M.S., neuroscience, University of Southern California
2003 Bachelor of Medicine, Fudan University, Shanghai Medical College (formerly Shanghai Medical University)

PROFESSIONAL EXPERIENCE

2011–Present Analysis Group; London, UK
 Vice President (2019–Present)
 Manager: Health economics and outcomes research (2015–2018)
 Associate: Health economics and outcomes research (2011–2014)

2003–2011 University of Southern California; Los Angeles, CA
 Research Assistant: Hemophilia utilization group study (2007–2011)
 Baxter Research Fellow: Grant from Baxter Healthcare Corp. (2008–2011)
 Teaching Assistant: Department of Biology (2005–2006)
 Research Assistant: Longevity Institute (2003–2006)

Summer 2009 Analysis Group; Boston, MA
 Associate Intern

2001–2002 Zhongshan Hospital; Shanghai, China
 Clinical Intern

SELECTED PUBLICATIONS

Peer-reviewed Journals

- Zhou Z, Fan Y, Tang W, Liu X, Thomason D, **Zhou ZY**, Macaulay D, Fischer A. Economic Burden among Commercially Insured Patients with Systemic Sclerosis in the United States. *J Rheumatol*. 2019 Feb 15. pii: jrheum.180445. doi: 10.3899/jrheum.180445. [Epub ahead of print]
- **Zhou ZY**, Tang W, Villa KF. Indirect costs associated with premature mortality among those with veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan dysfunction post-hematopoietic stem-cell-transplant. *Clinicoecon Outcomes Res*. 2018 Dec 17;11:13-22.
- Zhou Z, **Zhou ZY**, Kellar SS, Sikirica V, Xie J, Grebla R. Treatment patterns among adults with ADHD receiving long-acting therapy. *Am J Manag Care*. 2018 Jul;24(8 Spec No.):SP329-SP337.
- Li J, Sasane M, Zhao J, Horton VG, Zhang P, Ricculli ML, **Zhou ZY**, Signorovitch J. Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-Small-Cell Lung Cancer: A Network Meta-Analysis. *Adv Ther*. 2018 Jun 15.
- **Zhou ZY**, Mutebi A, Han S, et al. Cost-effectiveness of Ceritinib in Previously Untreated Anaplastic Lymphoma Kinase-positive Metastatic Non-small Cell Lung Cancer in the United States. *J Med Econ*. 2018 Jun;21(6):577-586.
- Zhou Z, **Zhou ZY**, Kelkar SS, Sikirica V, Xie J, Grebla R. Medication Use in Adults with Attention Deficit/Hyperactivity Disorder in a Commercially-insured Population in the United States. *Curr Med Res Opin*. 2018 Apr;34(4):585-592.
- Hurry M, **Zhou ZY**, Zhang J, Zhang C, Fan L, Rebeira M, Xie J. Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada. *J Med Econ*. 2016 Oct;19(10):936-44.
- Liu G, Zhang J, **Zhou ZY**, Li J, Cai X, Signorovitch J. Association Between Time to Progression and Subsequent Survival in Ceritinib-treated Patients with Advanced ALK-positive Non-small Cell Lung Cancer. *Curr Med Res Opin*. 2016 Nov;32(11):1911-1918.
- Tan DS, Araújo A, Zhang J, Signorovitch J, **Zhou ZY**, Cai X, Liu G. Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls. *J Thorac Oncol*. 2016 Sep;11(9):1550-7.
- Strand V, Husni E, Griffith J, **Zhou ZY**, Signorovitch J, Ganguli A. Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US. *Rheumatol Ther*. 2016 Dec;3(2):305-322.
- **Zhou ZY**, Griffith J, Du EX, Chin D, Betts KA, Ganguli A. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis. *Adv Ther*. 2016 May;33(5):807-23.
- KA Betts, J Griffith, A Friedman, **ZY Zhou**, JE Signorovitch, A Ganguli. An Indirect Comparison and Cost per Responder Analysis of Adalimumab, Methotrexate and Apremilast in the Treatment of Methotrexate-naïve Patients with Psoriatic Arthritis. *Curr Med Res Opin*. 2016;32(4):721-9.
- **Zhou ZY**, Sun S, Chopra P, Zhong Y, Totev T, Signorovitch J. Health Resource Use and Costs of Vilazodone and Other Selective Serotonin Reuptake Inhibitors in Treating Major Depressive Disorder. *J Med Econ*. 2015 Jun 29:1-36.

- Xie J, Hao Y, **Zhou ZY**, Qi CZ, De G, Glück S. Economic Evaluations of Everolimus Versus Other Hormonal Therapies in the Treatment of HR+/HER2- Advanced Breast Cancer From a US Payer Perspective. *Clin Breast Cancer*. 2015 Apr 23. pii: S1526-8209(15)00091-9.
- **Zhou ZY**, Koerper M, Johnson K, et al. Burden of Illness: Direct and Indirect Costs among Persons with Hemophilia in the United States. *J Med Econ* 2015;18(6):457-65.
- Hurvitz S, Guerin A, Brammer M, Guardino E, **Zhou ZY**, Latremouille Viau D, Wu EQ, Lalla D. Investigation of Adverse-Event-Related Costs for Patients with Metastatic Breast Cancer in a Real-World Setting. *Oncologist*. 2014;19(9):901-8.
- Niu X, Poon JL, Riske B, **Zhou, ZY**, et al. Physical Activity and Health Outcomes in Persons with Haemophilia B. *Haemophilia* (2014), 1–8.
- Yang H, Chaudhari P, **Zhou ZY**, et al. Budget Impact Analysis of Liposomal Amphotericin B and Amphotericin B Lipid Complex in the Treatment of Invasive Fungal Infections in the United States. *Appl Health Econ Health Pol*. 2014;12 (1), 85-93
- **Zhou ZY**, Hay JW. Efficacy of Bypassing Agents in Patients with Hemophilia and Inhibitors: A Systematic Review and Meta-Analysis. *Clin Ther*. 2012;34(2):434-45.
- Poon JL, **Zhou ZY**, Doctor JN, et al. Quality of Life in Hemophilia A: Hemophilia Utilization Group Study Va (HUGS-Va). *Haemophilia*. 2012;18(5):699-707
- Johnson KA, **Zhou ZY**. Costs of Care in Hemophilia and Possible Implications of Health Care Reform. *Hematology Am Soc Hematol Educ Program*. 2011;2011:413-8.
- Hay JW, **Zhou ZY**. Economic Comparison of APCC vs rFVIIa for Mild-to-Moderate Bleeding Episode in Hemophilia Patients with Inhibitors. *Haemophilia*. 2011;17(5):e969-74.
- **Zhou ZY**, Riske B, Forsberg AD, et al. The Association of Social, Demographic, Insurance, and Clinical Factors with Self-Reported Barriers to Hemophilia Care in Patients with Factor VIII Deficiency. *Am J Prev Med*. 2011;41(6 Suppl 4):S346-53
- **Zhou ZY**, Wu J, Baker J, et al. Hemophilia Utilization Group Study-Part Va (HUGS Va): design, methods and baseline data. *Haemophilia*. 2011;17(5):729-36
- Hay JW, **Zhou ZY**. Systematic Literature Review of Economics Analysis on Treatment of Mild-to-Moderate Bleeds with aPCC Versus rFVIIa. *J Med Econ*. 2011;14(4):516-25.
- Hay JW, **Zhou ZY**. Commentary on Knight, Et Al.: A Systematic Review of the Cost-Effectiveness of rFVIIa and APCC in the Treatment of Minor/Moderate Bleeding Episodes for Haemophilia Patients with Inhibitors. *Haemophilia*. 2010;16(2):366-8; discussion 369-71.
- Gao YQ, Gao H, **Zhou ZY**, Lu SD, Sun FY. Expression of Transient Receptor Potential Channel 4 in Striatum and Hippocampus of Rats Is Increased After Focal Cerebral Ischemia. *Sheng Li Xue Bao*. 2004;56(2):153-7.

Workshops

- Advancements in methods of survival benefit estimation for novel oncology drugs and their applications in ICER reviews. Educational Symposium at ISPOR 2018, Baltimore Maryland, May 19-23, 2018

- Evaluating survival benefits in technology appraisals of innovative oncology drugs: challenges and practical solutions. Educational Symposium at ISPOR 20th Annual European Congress, Glasgow, Scotland, November 4-8, 2017

Selected Poster or Podium Presentations

- **Zhou ZY**, Parikh K, Chai X, Rokito A, Udeze C, Xie J, and Agarwal A. Cost-Effectiveness Analysis of Lenalidomide for Maintenance Therapy after Autologous Stem Cell Transplant (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM) Patients: A United States Payer Perspective. Poster presentation at ASH 2018, San Diego, December 1-4, 2018
- Mahajerin A, **Zhou ZY**, Raimundo K, Patel A, Han S, Ji Y, Zhong J, and Betts K. Model of Short and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A. Poster presentation at ASH 2018, San Diego, December 1-4, 2018
- Griffin JD, Storm M, Wilhelm K, Boscoe A, Macaulay D, **Zhou ZY**, Faust E and Cheung C. Treatment Patterns and Healthcare Resource Utilization in Patients with Relapsed/Refractory Acute Myeloid Leukemia and a Subset with IDH1-Mutation: A United States Medical Chart Review Study. ASH 2018, San Diego, December 1-4, 2018
- Xie J, Knoll S, Slowley A, Bensimon A, Vieira J, Chilcott J, Paisley S, **Zhou ZY**. Cost-effectiveness of ceritinib in previously untreated ALK-positive non-small cell lung cancer in the United Kingdom. Poster presentation at ISPOR 2018, Baltimore, MD, May 19–23, 2018
- Thomason D, Yu Y, Zhou Z, Tang W, Liu X, **Zhou ZY**, Macaulay D, Fischer A. Patterns of Immunosuppressive Therapy among Patients with Newly Diagnosed Systemic Sclerosis (SSc) and SSc-Associated Interstitial Lung Disease (SSc-ILD). Poster presentation at Academy of Managed Care & Specialty Pharmacy Annual Meeting, Boston, MA, April 23–26, 2018
- **Zhou ZY**, Tang W, Villa K. A model estimating work productivity loss due to premature death associated with hepatic veno-occlusive disease/sinusoidal obstruction syndrome among hematopoietic stem cell transplant patients in the United States. Poster presentation at 14th Annual Meeting for the Hematology/Oncology Pharmacy Association, Denver, CO, March 21–23, 2018
- Zhou Z, Yu Y, Tang W, Liu W, Thomason D, **Zhou ZY**, Macaulay D, Fischer A. Burden of illness of systemic sclerosis among commercially insured patients. Poster presentation at the 5th Systemic Sclerosis World Congress, Bordeaux, France, February 15–17, 2018
- Zhou Z, Yu Y, Liu W, Tang W, **Zhou ZY**, Thomason D, Macaulay D, Fischer A. Burden of Illness of Systemic Sclerosis with Interstitial Lung Disease among Commercially Insured Patients. American Thoracic Society 2018 International Conference, San Diego, CA, May 18–23, 2018
- **Zhou ZY**, Bensimon A, Cheng J, Dalal A. Budget impact analysis of dabrafenib and trametinib combination therapy in the treatment of BRAF V600E-mutant advanced non-small cell lung cancer in the United States. Poster presentation at ISPOR 20th Annual European Congress, Glasgow, Scotland, November 4–8, 2017
- Mutebi A, **Zhou ZY**, Ricculli ML, Han S, Xie J, Dalal A, Culver K. Budget impact analysis of first-line ceritinib in the treatment of ALK+ metastatic non-small cell lung cancer (NSCLC) in the United States. Poster presentation at ISPOR 20th Annual European Congress, Glasgow, Scotland, November 4-8, 2017

- Dalal A, **Zhou ZY**, Tang W, Ricculli ML, Guerin A, Sasane M, Wu K, Culver K, Otterson G, Pennell N. Cost consequence analysis of different gene mutation testing modalities for BRAFV600E mutation in advanced non-small cell lung cancer using a decision analytic model. Poster presentation at ISPOR 20th Annual European Congress, Glasgow, Scotland, November 4–8, 2017
- **Zhou ZY**, Mutebi A, Han S, Bensimon A, Ricculli ML, Xie J, Dalal AA, Culver KW. Cost-effectiveness of ceritinib in previously untreated alk-positive non-small cell lung cancer in the United States. Poster presentation at Academy of Managed Care Pharmacy, Nexus, Dallas, TX, October 16–19, 2017
- Zhou Z, **Zhou ZY**, Kelkar SS, Xie J, Grebla R. Adherence and Persistence on Long-acting Monotherapy and Combination Therapy in Adults with Attention-Deficit Hyperactivity Disorder (ADHD) in the US. Poster presentation at Academy of Managed Care Pharmacy, Nexus, Dallas, TX, October 16–19, 2017
- Ailawadhi S, Parikh K, Zhou Z, Tang W, Clancy Z, Cheung C, **Zhou ZY**, Xie J, Abouzaid S. Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: A Seer-Medicare analysis. 59th Annual Meeting of the American Society of Hematology, Washington, DC, December 9–12, 2017
- Abouzaid S, Parikh K, **Zhou ZY**, Zhou Z, Tang W, Xie J, Patel MI. Disparities in treatment patterns and outcomes between Caucasian and African American patients with multiple myeloma (MM). Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 3–7, 2016
- Chaudhuri KR, Terasawa E, Jalundhwala Y, Macaulay D, Ayyagari R, **Zhou ZY**, Marshall T, Chatamra K, Yucel A, Sail K. Non-motor symptoms in advanced Parkinson's disease patients treated with levodopa/carbidopa intestinal gel, deep brain stimulation, or continuous subcutaneous apomorphine: A systematic literature review and pooled analysis. Poster presentation at the 20th International Congress of Parkinson's Disease and Movement Disorders, Berlin, Germany, June 19–23, 2016
- Zhang J, Song Y, **Zhou ZY**, Zhang C, Signorovitch J. Jie Zhang, The impacts on work productivity from ceritinib compared with chemotherapy for crizotinib-experienced ALK+ non-small cell lung cancer. Podium presentation at the 6th European Lung Cancer Conference, Geneva, Switzerland, April 13–16, 2016
- **Zhou ZY**, Griffith J, Ganguli A, Du EX, Betts, K. Economic Burden of Switching to an Anti-Tumor Necrosis Factor (anti-TNF) Versus a Non-Tumor Necrosis Factor (non-TNF) Biologic Therapy Among Patients with Rheumatoid Arthritis. Poster presentation at the 2015 ACR/ARHP Annual Meeting, San Francisco, California, USA, November 6–11, 2015
- **Zhou ZY**, Zhang J, Fan L, Zhang C, Xie J. Cost-effectiveness of Ceritinib in the Treatment of Previously Treated Anaplastic Lymphoma Kinase-positive (ALK+) Advanced or Metastatic Non-small Cell lung Cancer in the United Kingdom. Poster presentation at the ISPOR 18th Annual European Congress, Milan, Italy, November 7–11, 2015
- **Zhou ZY**, Hurry M, Zhang J, Fan L, Zhang C, Xie J. Cost-effectiveness of Ceritinib in Previously Treated Patients with Crizotinib in Anaplastic Lymphoma Kinase-positive (ALK+) Non-small Cell lung Cancer in Canada. Poster presentation at the ISPOR 18th Annual European Congress, Milan, Italy, November 7–11, 2015

- Zhang J, **Zhou ZY**, Cai X, Signorovitch J. Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-small Cell lung Cancer(NSCLC): A Network Meta-Analysis. Poster presentation at the ISPOR 18th Annual European Congress, Milan, Italy, November 7–11, 2015
- Liu G, Zhang J, **Zhou ZY**, Li J, Cai X, Signorovitch J. Time to Progression and Post-Progression Survival in ALK+ Ceritinib-treated NSCLC. Oral presentation at the 16th World Conference on Lung Cancer (WCLC 2015), Denver, CO, September 6–9, 2015
- Tan DS, Araujo A, Zhang J, Signorovitch JE, **Zhou ZY**, Cai X, Liu G. Comparative Efficacy of Ceritinib and Crizotinib in Previously Treated Crizotinib-naive Anaplastic Lymphoma Kinase-positive (ALK+) Advanced or Metastatic Non-small Cell lung Cancer (NSCLC): An Adjusted Indirect Comparison. Poster presentation at American Society of Clinical Oncology (ASCO 2015) Annual Meeting, Chicago, IL, May 29–June 2, 2015
- **Zhou ZY**, Signorovitch JE, Griffith JM, Zhong Y, Ganguli A. Economic Evaluation of Timely Versus Delayed Use of Anti-Tumor Necrosis Factor (TNF) Biologics in the Treatment of Psoriatic Arthritis (PsA) in the US. Poster presentation at the ISPOR 20th Annual International Meeting, Philadelphia, PA, May 16–20, 2015
- **Zhou ZY**, Sun SX, Chopra P, Zhong Y, Totev T, Signorovitch JE. Healthcare Utilization and Costs Among Adults with Major Depressive Disorder Treated with Vilazodone vs. Other Selective Serotonin Reuptake Inhibitors. Poster presentation at the ISPOR 20th Annual International Meeting, Philadelphia, PA, May 16–20, 2015
- Xie J, Hao Y, **Zhou ZY**, Qi C, De G, Gluck S. Cost Effectiveness of Everolimus plus Exemestane for the Treatment of Advanced HR+, HER2- Breast Cancer in the United States. Poster presentation at Academy of Managed Care Pharmacy (AMCP) 2014 Nexus Meeting, Boston, Massachusetts, October 7–10, 2014
- Wolff M, **Zhou ZY**, Signorovitch J, Shaw JW and Ganguli A. Cost-Effectiveness Of Different Treatment Sequences Including Adalimumab In The Treat-To-Target Framework For Early Rheumatoid Arthritis In Germany. Oral presentation at the American College of Rheumatology (ACR) and the Association for Rheumatology Health Professionals (ARHP) annual meeting, San Diego, October 26–30, 2013
- Chaudhari P, Yang H, **Zhou ZY**, et al. Budget Impact Analysis of Liposomal Amphotericin B and Amphotericin B Lipid Complex for Treating Invasive Fungal Infections in Hospitalized Patients. Poster presentation at the ISPOR 18th Annual International Meeting, New Orleans, LA, May 18–22, 2013
- **Zhou ZY**, Fan L, Chen E, Xie J, Wu EQ. An Economic Model of Improved Acute Stroke Care in the Management of Acute Ischemic Stroke from a State Medicaid Perspective. Poster presentation at the International Stroke Conference, Honolulu, Hawaii, February 5–7, 2013
- Xie JP, **Zhou ZY**, Bai CN, et al. Cost-Effectiveness Analysis of Mirabegron versus Tolterodine Extended Release in the Treatment of Patients with Overactive Bladder in the United States. Presented at the ISPOR 15th Annual European Congress, Berlin, Germany, November 3–7, 2012

- Hurvitz SA, Guérin A, Brammer M, Guardino E, **Zhou ZY**, Kaminsky MS, Wu EQ, Lalla D. Comprehensive investigation of adverse event (age)-related costs in patients with metastatic breast cancer (MBC) treated with first- and second-line chemotherapies. Poster presentation at the ISPOR 15th Annual European Congress 2012, ICC Berlin, Germany, November 3–7, 2012
- Yang M, Yang M, Skup M, **Zhou ZY**, et al. Cost-effectiveness of Adalimumab for the Treatment of Crohn's Disease in Germany. Poster presentation at the ISPOR 15th Annual European Congress 2012, ICC Berlin, Germany, November 3–7, 2012
- Hurvitz SA, Guerin A, Brammer MG, Guardino E, **Zhou ZY**, et al. Comprehensive investigation of adverse event (AE)-related costs in patients with metastatic breast cancer (MBC) treated with first- and second-line chemotherapies. Poster presentation at American Society of Clinical Oncology (ASCO) annual meeting, Chicago, IL, 2012
- Poon J, Lou M, **Zhou ZY**, et al. Characterizing Excessive School and Work Absenteeism in Hemophilia A. Poster presentation at the World Federation of Hemophilia (WFH) World Congress, Paris, France, 2012
- Johnson KA, Curtis R, Koerper M, Lou M, Poon JL, Riske B, **Zhou ZY**. Healthcare Utilization and Cost of Care – Insights from the Hemophilia Utilization Group Study (HUGS). Podium presentation at the XXX International Congress of the World Federation of Hemophilia, Paris, France, July 8–12, 2012
- Johnson KA, **Zhou ZY**, et al. Burden of Illness: Direct and Indirect Costs Among Persons with Hemophilia A. Poster presentation at the 2nd National Conference on Blood Disorders in Public Health, Atlanta, GA, March 10–12, 2012 (Best poster presentation award)
- Poon J, Lou M, **Zhou ZY**, et al. Health Literacy in Persons with Hemophilia B. Poster presentation at the 2nd National Conference on Blood Disorders in Public Health, Atlanta, GA, March 10–12, 2012
- Poon J, Lou M, **Zhou ZY**, et al. Sociodemographics, Clinical Characteristics and Health-Related Quality of Life among People with Hemophilia A and B. Poster presentation at the National Hemophilia Foundation (NHF) meeting, Chicago, IL, 2011
- **Zhou ZY**, Hay JW. A systematic review and meta-analysis comparing the efficacy of bypassing agents in hemophilia patients with inhibitors. Poster presentation at the XXIII Congress of the International Society on Thrombosis and Haemostasis 57th Annual SSC Meeting, ICC Kyoto, Kyoto, Japan, July 23–28, 2011
- **Zhou ZY**, Ullman M, Koerper, et al. Characterizing direct costs associated with hemophilia A: a resource-based cost analysis. Poster presentation at the ISPOR Annual International Meeting, Baltimore, MD, May 21–25, 2011 (Best student poster finalist)
- Lou M, **Zhou ZY**, et al. Utilizing a paper standard gamble instrument to assess health utility in patients with hemophilia B. Poster presentation at the ISPOR Annual International Meeting, Baltimore, MD, May 21–25, 2011
- Poon J, Lou M, Doctor J, **Zhou ZY**, et al. Hemophilia-related quality of life in hemophilia B. Poster presentation at the ISPOR Annual International Meeting, Baltimore, MD, May 21–25, 2011 (Best student poster finalist)

- **Zhou ZY**, et al. Bleeding episodes and indirect costs among patients with hemophilia A - the Hemophilia Utilization Group Study Part Va (HUGS Va). Podium presentation at the National Hemophilia Foundation (NHF) meeting, New Orleans, LA, 2010
- Lou M, **Zhou ZY**, et al. The Hemophilia Utilization Group Study Part-Vb: characterization of baseline data. Poster presentation at the National Hemophilia Foundation (NHF) meeting, New Orleans, LA, May 15–19, 2010
- **Zhou ZY**, et al. Health care utilization and cost in persons with factor VIII deficiency: results of the HUGS-Va study. Poster presentation at the XXIXth International Congress of the World Federation of Hemophilia, Buenos Aires, Argentina, July 10–14, 2010
- **Zhou, ZY**, et al. Association of self-reported joint pain and motion limitation with clinical range of motion assessment in patients with hemophilia A. Poster presentation at the XXIXth International Congress of the World Federation of Hemophilia, Buenos Aires, Argentina, July 10–14, 2010
- **Zhou ZY**, et al. One year health care utilization and cost in patients with factor VIII deficiency: first year results, et al. Podium presentation at the National Hemophilia Foundation (NHF) meeting, San Francisco, CA, 2009
- Hay JW., **Zhou ZY**, Young G. Economic comparison of APCC vs rFVIIa for mild-to-moderate bleeding episode in hemophilia patients with inhibitors. Poster presentation of the XXII Congress of the International Society of Thrombosis and Haemostasis, Boston, MA, July 11–16, 2009
- Hay JW, **Zhou ZY**, aPCC versus rFVIIa in treatment of hemophilia patients with inhibitors: a structured review of the pharmacoeconomic literature. Poster presentation of the XXII Congress of the International Society of Thrombosis and Haemostasis, Boston, MA, July 11–16, 2009
- **Zhou ZY**, et al. Healthcare utilization in persons with severe hemophilia A on prophylactic vs. episodic replacement. Poster presentation at the Hemostasis & Thrombosis Research Society (HTRS) Scientific Symposium, Chicago, IL, 2009 (Young investigator award)
- **Zhou ZY**, Globe D, Ullman M, et al. Health care utilization and factor cost in hemophilia. Poster presentation at the ISPOR Annual International Meeting, Orlando, FL, May 16–20, 2009
- **Zhou ZY**, et al. Health insurance coverage for adults and children with hemophilia: HUGS-V: A. Poster presentation at the National Hemophilia Foundation (NHF) meeting, Denver, CO, 2008
- **Zhou ZY**, Wu J, Globe D, et al. Factors associated with lower health-related quality of life (HRQOL) in adults with factor VIII deficiency. Poster presentation at the ISPOR Annual International Meeting, Toronto, Canada, May 3–7, 2008
- Curtis R, **Zhou ZY**, et al. Hemophilia Utilization Group Study (HUGS V): baseline data and factor utilization. Poster presentation at the XXVIII International Congress of the World Federation of Hemophilia, Istanbul, Turkey, June 1–5, 2008
- **Zhou ZY**, et al. Hemophilia Utilization Group Study (HUGS V): summary of baseline demographics, clinical characteristics, barriers to care, arthropathy and quality of life. Poster presentation at the National Hemophilia Foundation (NHF) meeting, Orlando, FL, 2007
- Riske B, Forsberg A, **Zhou ZY**, et al. Association of social demographics and clinical factors with barriers to hemophilia care in patients with factor viii deficiency. Poster presentation at American Public Health Association (APHA) 135th annual meeting, Washington, DC, November 3–7, 2007